Shares of Twitter Inc (NYSE:TWTR) took a beating today
Shares of Twitter Inc (NYSE:TWTR) took a beating today after reporting earnings that were far worse than expected. Going into earnings there had been so much hype because President Donald Trump uses Twitter as one of his main forms of communication. The hope had been that there would be a sharp increase in usage because of it. This did not happen. The stock ran up into earnings and is now getting slammed after earnings. It is trading down at $16.49 -2.23 (-11.91%) and is testing a major trend line. Should the trend line break (as seen on the stock chart below), the stock will fall straight to $14, its all-time lows. I personally think it is a going to $14 before any sort of bottom is in place. The company still is not doing a good job of monetizng the platform. For a buyout to occur, the stock will have to drop sharply and a big player will have to find some sort of silver lining. See you at $14.00.
.
Price target $14 as investors sell Twitter Inc ugly earnings
Twitter Inc. (TWTR) Stock Research Links
I was trained as a psychologist, then I applied what I knew to stock trading. Stocks are representing emotion of those who buy/sell them. I post all of my trades on
Insert-tag-hereVerifiedInvesting.com where they are confirmed for legitamacy by their independent verification system. I've been trading since the 90s.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Celebrating Innovative Thought Leadership Accenture, KPMG, and Elsevier have been honored for their groundbreaking accomplishments in thought leadership, showcasing their significant influence across brand development, social impact, and industry standards. Recognition at the TLFT 2025 Awards iResearch Services has proudly unveiled the winners of the prestigious TLFT 2025...
Continue Reading
Aquestive Therapeutics made headlines back in 2024 with its stock getting a price target bump to $10 from H.C. Wainwright. This was right after they rolled out updates at a virtual investor event where they pitched their cutting-edge Adrenaverse technology. Traders were buzzing—was this the kind of news that’d drive shares up? Turns out, it was more than just fluff;...
Continue Reading
Valneva Begins Clinical Trials for Innovative Shigella Vaccine Valneva SE, a prominent specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech firm, have recently marked a significant milestone in vaccine research. They announced the initial vaccination in a pivotal Phase 2b controlled human infection model (CHIM) study focused on their tetravalent...
Continue Reading
Introducing a Revolutionary Vehicle Safety Accessory Every day, drivers encounter various challenges on the road, from navigating busy intersections to spotting pedestrians or hidden traffic signs. An innovative inventor recognized these challenges and developed the CORNER CAMERA, an inventive solution aimed at improving road safety for everyone. Understanding the CORNER...
Continue Reading
California Northstate University Announces Full Accreditation California Northstate University (CNU) has achieved a significant milestone by securing full accreditation for its College of Medicine from the Liaison Committee on Medical Education (LCME). This achievement underscores CNU’s unwavering dedication to promoting educational excellence, innovation, and the...
Continue Reading
